N/A
N=160
Retrospective Record-review Study in Patients Who Had Diabetic Foot Ulcer
Diabetic Foot Ulcer
Bottom Line
View on ClinicalTrials.gov: NCT05135130 ↗Enrolled (actual)
160
Serious AEs
—
Results posted
Mar 2026
Primary outcome: Primary: Demographic Characteristics: Weight (Mean) — 73.7; 78.3 kg
Study Design & Population
- Study type
- Observational
- Phase
- N/A
- Interventions
- ON101 Cream (Drug)
- Age
- Adult, Older Adult · 20+ yrs
- Sex
- All
- Sponsor
- Oneness Biotech Co., Ltd.
- Primary completion
- Jan 2022
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Demographic Characteristics: Weight (Mean) |
73.7; 78.3 | — |
| PRIMARY Demographic Characteristics: BP (Mean) |
132; 144; 74.8; 77.4 | — |
| PRIMARY Demographic Characteristics: ABI (Mean) |
1.1; 1.0; 0.9; 1.1 | — |
| PRIMARY Medical Costs Due to DFUs |
19852.0; 25671.9 | — |
| PRIMARY Percentage of Amputation |
0.00; 1; 1; 2; 1; 3 | — |
Summary
The purpose of the study is to evaluate the medical cost of illness for DFUs on the patients who had used ON101 or Aquacel® in the ON101CLCT02 trial.
Eligibility Criteria
No additional inclusion or exclusion criteria will be applied.
Data sourced from ClinicalTrials.gov (NCT05135130). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.